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Abstract
The possibility of engineering the immune system in a targeted fashion using biomaterials such as 
nanoparticles has made considerable headway in recent years. However, little is known as to how 
modulating the spatial presentation of a ligand augments downstream immune responses. In this 
report we show that geometric manipulation of phosphatidylserine (PS) through fabrication on 
rod-shaped PLGA nanoparticles robustly dampens inflammatory responses from innate immune 
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cells while promoting T regulatory cell abundance by impeding effector T cell expansion. This 
response depends on the geometry of PS presentation as both PS liposomes and 1 micron 
cylindrical PS-PLGA particles are less potent signal inducers than 80 × 320 nm rod-shaped PS-
PLGA particles for an equivalent dose of PS. We show that this immune tolerizing effect can be 
co-opted for therapeutic benefit in a mouse model of multiple sclerosis and an assay of organ 
rejection using a mixed lymphocyte reaction with primary human immune cells. These data 
provide evidence that geometric manipulation of a ligand via biomaterials may enable more 
efficient and tunable programming of cellular signaling networks for therapeutic benefit in a 
variety of disease states, including autoimmunity and organ rejection, and thus should be an active 
area of further research.
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1. Introduction
Recent advances in multiple scientific fields, including materials science and immunology, 
are now converging to enable targeted, pathology-specific biological programming to 
promote health in living animals [1–4]. This is in part due to our increased understanding of 
the signaling pathways involved in a variety of disease states as well as our fundamental 
appreciation of the molecular interactions which underlie initiation and maintenance of 
immune responses. This information has been used to generate a new wave of therapeutic 
tools that program biological responses using rationally-designed biomaterials, including 
nanoparticles and hydrogels. Some examples of the programming potential of this new class 
of tools include more potent and sustained vaccine responses to pathogens [5–8], enhanced 
drug delivery and immunomodulation in the setting of cancer [9–18], amelioration of both 
acute and chronic inflammatory responses [19–22], and dampening autoimmunity and 
allergies through promotion of antigen-specific tolerance [23–25].
While the potential for nanotechnology to transform therapeutic approaches to the diseases 
that burden 21st century societies is readily apparent at this stage, there remain many 
unanswered mechanistic and design questions as relates to nanoparticle-mediated 
programming of biologic responses. In this report, we aimed to address one such 
fundamental question regarding the particulate presentation of a ligand that binds a cell 
surface receptor. This is a mechanistically critical question, as programming of biological 
responses will often require interface with cell surface receptors yet little is known as to how 
the geometric manipulation of ligands via biomaterials augments downstream biological 
signaling from the cell surface. Here, we use the term geometry to broadly define the three 
dimensional presentation of a ligand that can be manipulated through varying the size, 
shape, composition and biophysics of a particulate delivery vehicle. Given the recent finding 
that geometric manipulation of the erythropoietin cell surface receptor using diabodies can 
fundamentally alter downstream signaling effects, there is precedent for this concept [26].
Roberts et al. Page 2













To address this issue, we chose to use the cell membrane phospholipid phosphatidylserine 
(PS) as our model ligand for a cell surface receptor. PS is primarily localized on the inner 
membrane of cells until apoptosis triggers it to re-localize to the outer membrane where it 
can serve as an “eat-me” signal to phagocytes [27–29]. This is a critical means by which the 
body avoids aberrant immune response to self-antigens because the PS signal induces an 
anti-inflammatory program in the engulfing phagocyte which promotes tolerance to 
components of the dying cell. This is thought to be in part due to TGF-β1 release as well as 
triggering of cell surface receptors, including the PS receptor (PSR) and MERTK, a member 
of the TAM family of receptor tyrosine kinases [27,28], [30–32]. We hypothesized that 
particulate presentation of PS on a nanoparticle would mimic apoptotic cells and thus drive 
an anti-inflammatory program in innate immune cells. There is evidence for this using 
liposomal preparations of PS however we broadened our approach to specifically address 
how the geometry of PS presentation augmented its signaling effects and subsequent 
therapeutic potential [33–35]. In particular, we addressed how PS liposomes versus delivery 
of PS on 80 × 320 nm PLGA nanorods or 1 micron cylindrical PLGA particles affected 
downstream immune responses.
This latter feature of our paper – design control of particulate PS presentation – was made 
possible through using the Particle Replication in Non-Wetting Template (PRINT) process, 
which enables fabrication of particles of a homogenous size, shape, and charge composed of 
both lipids and polymers through a molding process [36–39]. We have previously shown that 
the PRINT process enables fabrication of nano- and microparticles made of poly lactic-co-
glycolic acid (PLGA) or PEG (poly-ethylene glycol) that do not induce immune activation at 
baseline in mouse and human cells. We have also shown these particles can be designed to 
target mammalian innate immune cells in vitro and in vivo or remain extracellular, thus 
making them an attractive tool for programming immune responses for therapeutic benefit 
[40–43].
In this report we show that geometric manipulation of PS programs the immune response 
towards an anti-inflammatory state that dampens effector T cell expansion while promoting 
T regulatory cell abundance in a tunable fashion. We show that this anti-inflammatory 
response may possibly be co-opted for therapeutic benefit in a variety of disease states, 
including autoimmunity using a mouse model of multiple sclerosis and transplantation 
medicine approaches using a model of allogeneic human T cell activation. These results 
strongly suggest that particulate delivery of a cell surface receptor ligand can trigger unique 
signaling effects through geometric manipulation of the surface membrane. Therefore, 
geometric and biophysical properties of particles should be included as part of baseline 
experiments that seek to further the field of programming biological responses as it is highly 
likely each ligand of therapeutic interest will have its own unique ‘best-in-class’ particle 
design parameters.
2. Materials and methods
2.1. PRINT particle fabrication and characterization
For the incorporation of PS (Avanti Polar Lipids, 840032) in the PRINT platform, PS and 
poly(D,L-lactide-co-glycolide) (PLGA) of lactide:glycolide 85:15 (Sigma Aldrich) were 
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dissolved separately in chloroform. The solutions of PS and PLGA were mixed at ratios of 
10:90 (PS:PLGA), and the sample was diluted to 2 wt% (mass/mass) solution with 
chloroform. A thin film of PS and PLGA was deposited on a 6″ × 12″ sheet of poly(ethylene 
terephthalate) (PET) by spreading 200 μL of solution using a #5 Mayer Rod (R.D. 
Specialties). The solvent was evaporated with heat. Fluorocur®, d = 80 nm × h = 320 nm, d 
= 1000 nm × h = 1000 nm prefabricated molds and 2000 g/mol polyvinyl alcohol (PVOH) 
coated PET sheets were provided by Liquidia Technologies. The PET sheet with the film 
was then placed in contact with the patterned side of a mold and passed through heated nips 
(Chem Instruments Hot Roll Laminator) at 130 °C and 80 psi. The mold was split from the 
PET sheet as they both passed through the hot laminator. The patterned side of the mold was 
then placed in contact with a sheet of PET sheet coated with 2000 g/mol PVOH. This was 
then passed through the hot laminator to transfer the particles from the mold to the PET 
sheet. The mold was then peeled from the PET sheet. The particles were removed by passing 
the PVOH coated PET sheet through motorized rollers and applying water to dissolve the 
PVOH to release the particles. To remove excess PVOH and unbound PS, the particles were 
purified and then concentrated by tangential flow filtration (Spectrum Labs). PS was 
resuspended in deionized, distilled water and did not undergo more than 1 freeze–thaw cycle 
during experimentation. The PLGA particles were imaged by scanning electron microscopy 
(SEM) by pipetting a 3 μL sample of particle on a glass slide. The sample was then dried 
and coated with 3 nm gold palladium alloy using a Cressington 108 auto sputter coater. 
Images were taken at an accelerating voltage of 2 kV using a Hitachi model S-4700 SEM. 
For size and zeta potential measurement, dynamic light scattering (DLS) (Malvern 
Instruments Nano-ZS) was used. The particles were suspended in 10 mM KCl solution for 
zeta potential measurements. PS was measured using an Agilent Technologies Series 1200 
HPLC with a C18 reverse phase column (Zorbax Eclipse XDB-C18, 4.6 × 100 mm, 3.5 
micron). A linear gradient from 85:15 of methanol with 0.1% trifluoroacetic acid (TFA): 
water with 0.1% TFA to 100% methanol with 0.1% TFA was run over 25 min at a flow rate 
of 1 ml/min. Particle samples were dissolved in an acetonitrile:water solution, and the PS 
was quantified using an ELSD detector. Liposomal PS formulations were generated through 
resuspension of unadulterated PS in sterile water.
2.2. Murine bone marrow-derived dendritic cell activation studies
Red blood cell-depleted bone marrow cells were harvested from the femurs and tibias of 
C57BL/6 mice as previously described [44]. These cells were cultured with 5 ng/ml GM-
CSF in complete media (RPMI 1640 media containing 10 mM HEPES, 1 mM L-glutamine, 
100 U/ml penicillin, 100 μg/ml streptomycin, 50 μM β-mercaptoethanol and 10% heat 
inactivated FBS) at 37 °C for 6 days and purified using anti-CD11c+ beads (MACS). The 
six-day old bone marrow-derived dendritic cells (BMDCs) were incubated with PS-loaded 
PLGA nanoparticles (25 μM PS), PS alone (25 μM), or blank PLGA nanoparticles at 37 °C 
for 4 h, and the BMDCs were subsequently washed and stimulated with a Th1-like input 
(LPS/IFNγ). Eighteen hours post-stimulation, the BMDCs and media were separated for 
analysis. Cells were stained with an APC-labeled CD86 antibody (eBioscience, 17-0862-81) 
and the cell populations were quantified by flow cytometry analysis (CYAN Flow 
Cytometer). Mouse IL-6 (BD, 555240), mouse IL-12 p40 (BD, 555165), mouse PGE2 
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(Abcam, ab133055) ELISA sets were used for the analysis of the supernatant and were read 
using a fluorescence plate reader.
2.3. Myelin-specific murine T cell activation studies
Mouse T cells were purified from spleens of 2D2 mice, a genetically engineered mouse 
model with only T cells expressing T cell receptors to MOG, using anti-CD4+ beads 
(MACS) [45]. Bone-marrow derived DCs were incubated with PS-loaded PLGA nano-
particles (12, 25, or 50 μM PS), PS alone (12, 25, or 50 μM), or blank PLGA nanoparticles 
at 37 °C for 4 h, and the cells were subsequently washed. For myelin-specific T cell 
activation, 5 × 104 DCs treated with PS-loaded PLGA nanoparticles, PS alone, or blank 
PLGA nanoparticles at 37 °C for 4 h were pulsed with MOG35–55 peptide (50 μg/ml) and 
then incubated with 2 × 105 T cells for 48 h. The cells and media were separated, and the 
supernatant was probed for mouse IFNγ (Biolegend, 430806), mouse IL-2 (BD, 555148), 
mouse IL-6 (BD, 555240) mouse TNFα (BD, 555268). T-cells were stained with IL-10 
(eBioscience, 12-7101) and FOXP3 (eBioscience, 17-5773-82) to identify the Treg 
population using flow cytometry.
2.4. EAE animal studies
All animal studies were performed with the approval of the UNC Institutional Animal Care 
and Use Committee (IACUC). EAE was performed as previously described [45,46]. Briefly, 
MOG35–55 peptide (Genemed Synthesis Inc) was emulsified in complete Freund's adjuvant 
and mixed with heat-killed mycobacterium tuberculosis (4 mg/ml) using a luer-lock syringe 
system (Cadence, Inc). The emulsion was administered via subcutaneous injection to 
C57BL/6 mice on day 0. On day 7, which corresponded with the start of tail paralysis, PS 
alone (50 μg), PS-loaded 80 × 320 nm PLGA nanoparticles (50 μg PS), or an equivalent 
dose of blank 80 × 320 nm PLGA nanoparticles were administered via tail vein injection 
daily for 4 days. The following scale was used to assess clinical scores: 0 = Normal mouse, 
no overt sign of disease, 0.5 = Partial tail paralysis (loss of tip tail tonus), 1 = Limp tail or 
hind limb weakness but not both, 2 = Limb tail and hind limb weakness, 3 = Partial hind 
limb paralysis, 4 = Complete hind limb paralysis, 5 = Moribund state, sacrifice for humane 
reasons [46]. Results are indicative of a combination of two independent experiments.
2.5. Human mixed lymphocyte reaction studies
Blood was collected from healthy donors or leukapheresed patients in accordance with the 
University of North Carolina's Office of Human Research Ethics (IRB #12–1858 and #05–
2860). Donors provided written informed consent and samples were anonymized and de-
identified prior to use in the described studies. Peripheral blood mononuclear cells (PBMCs) 
were isolated from healthy donors using Ficoll Paque Premium (Fisher, 45-001-75). 
Dynabeads® Untouched™ Human CD4 T cells kit (Life Technologies, 11352D) were then 
used to isolate T cells. Allogenic T cell activation was performed by mixing 2 × 105 CD4+ T 
cells from 2 donors with 5 × 104 DCs isolated from 1 donor. DCs were treated with PS-
loaded PLGA nanoparticles (25 μM PS), PS alone (25 μM), or blank PLGA nanoparticles at 
37 °C for 4 h prior to co-culture with T cells. The cells and media were separated after 7 
days and the supernatant was probed for human IFNγ (BD, 555142). Human immune cell 
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flow analysis was performed with antibodies to either CD11c (eBio-science, 25-0116-42) or 
CD3 (eBioscience, 12-0037-42) on a CYAN Flow Cytometer.
2.6. Statistical analysis
All statistical comparisons were performed on GraphPad Prism (version 6.04). Two-tailed t-
tests and ANOVA followed by Tukey post-hoc analysis were performed as indicated. A p-
value of 0.05 or less was considered statistically significant.
3. Results
3.1. Fabrication and characterization of particles
We chose to fabricate 80 × 320 nm PLGA nanorods and 1 micron PLGA cylinders using the 
PRINT platform with and without encapsulated PS. We have previously published PRINT 
particles in this size range passively target both murine and human innate immune cells in a 
manner that does not significantly activate immune responses [40,41]. The PRINT process 
was used for fabrication of both 80 × 320 nm and 1 μm PS-loaded PLGA particles with a 
pre-particle solution composed of 10 wt% PS. The post-processed loading was determined 
to be 8 ± 2 wt% and 11 ± 3 wt% PS, respectively. As measured by dynamic light scattering, 
both PS-loaded PLGA nanorods and blank PLGA nanorods were ~210 nm in hydrodynamic 
diameter with PDI of less than or equal to 0.1. The PLGA cylinders had an average 
hydrodynamic diameter of ~1.2 microns with a PDI of ~0.7 for both the blank and PS-
loaded particles (Table 1). SEM images of the particles can be seen in Fig. 1.
The zeta potential for the PS-loaded PLGA nanorods was −22 mV and −6.3 mV for the 
blank PLGA nanorods. The blank PLGA cylinder zeta potential was −32 mV whereas the 
PS-loaded PLGA cylinders had a zeta potential of −39 mV. The incorporation of PS 
significantly modified the negative charge of the resulting particles as a result of the anionic 
nature of the lipid. In addition, we evaluated the PS release kinetics in 1 × PBS using sink 
conditions and found that 90% of PS was released from the 80 × 320 nm PRINT particles by 
4 h, while less than 15% of PS was released from the 1 micron cylinders by 4 h 
(Supplemental figure 1). Lastly, unadulterated, resuspended PS generated liposomes of 878 
nm with a PDI of 1. This high PDI value indicates a broad size range of PS liposomes above 
and below the 878 nm average.
3.2. Particulate delivery of PS down-regulates the inflammatory response in dendritic cells
The innate immune response is critical in both triggering and resolving inflammatory 
responses as well as educating adaptive immune responses in large part via signaling 
through a number of pattern recognition receptor families and cytokine receptors [47,48]. As 
dendritic cells are key mediators of the innate immune response and serve a crucial role as 
antigen presenting cells in driving adaptive immune responses, we sought to address how 
geometric manipulation of PS could augment the immune response of dendritic cells (DC) to 
inflammatory stimuli. In particular, we evaluated the effect of PS-loaded PLGA nanorods on 
the inflammatory response in BMDCs stimulated with a Th1-like input (LPS/IFNγ) for 18 h. 
BMDCs treated with 80 × 320 nm PLGA nanorods encapsulating 25 μM of PS (PS 
Nanorod) showed a significant suppression of the IL-6 and IL-12 inflammatory response 
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compared to either 25 μM of liposomal PS (PS LIPO) or blank PLGA nanorods (BLK 
PRINT) (Fig. 2A). This cytokine suppression was consistent across a time range from 4 hrs 
to 18 hrs and was also found when assaying for the inflammatory mediators prostaglandin 
E2 and TNF-α (Supplemental figures 2 and 3).
Quantification of CD86 expression, an important DC receptor necessary for T cell 
stimulation, showed that PS nanorods inhibited DC maturation as evidenced by a near 
complete abrogation of CD86 upregulation in response to LPS/IFNγ. In contrast, liposomal 
PS and blank PLGA particles did not suppress CD86 upregulation (Fig. 2B). Interestingly, 
surface expression of MHC Class II molecules (I-Ab) and CD80 was not significantly 
downregulated by PS nanorods (data not shown). These data indicate PS is able to suppress 
the inflammatory response of DC while also impeding DC maturation cues in a manner that 
is dependent on the geometric presentation of PS.
3.3. Particulate delivery of PS downregulates myelin-specific T cell activation and cytokine 
responses
As our initial findings suggested DC could be skewed away from inflammatory responses in 
the presence of 80 × 320 nm PS-loaded PLGA nanorods, we next asked whether this 
immunomodulation of innate immune cells could be used to dampen an established effector 
T cell response. To evaluate the effectiveness of the PS-loaded PLGA particles in reducing 
T-cell activation and cytokine production, we made use of transgenic 2D2 mice. These 
transgenic mice have T cell receptors (TCRs) that are specific for myelin oligodendrocyte 
glycoprotein (MOG), a critical protein involved in the myelination of nerves in the central 
nervous system and one of the components that the body attacks in MS [49]. Because T cells 
of 2D2 mice process MOG in a Th1-biased manner, this experimental system enabled us to 
address whether delivery of PS may dampen an already established pro-inflammatory 
immune response to a known antigen.
2D2 T cells were incubated with DC that had been exposed to particles or controls in the 
presence and absence of MOG. As expected, in the absence of MOG there was little to no 
detectable IL-2, IL-6, TNFα, or IFNγ released (data not shown). However, when MOG was 
added to the system, a pro-inflammatory and T cell proliferative environment was triggered 
as evidenced by the robust production of IL-2, IL-6, TNFα, and IFNγ (Fig. 3A). In this type 
of mixed culture, T cells are the source of IFNγ and IL-2, while both T cells and DC 
produce TNFα and IL6. Liposomal PS could dampen production of these cytokines to 
variable degrees, but this effect required the highest PS dose used (50 μM). In contrast, 
particulate delivery of PS on 80 × 320 nm PLGA nanorods completely abolished IL-2 and 
IFNγ production and significantly reduced IL-6 and TNFα release to their baseline levels at 
the lowest PS dose used (12.5 μM) with only minimal enhancement seen when escalating 
the amount of PS delivered on nanorods.
Furthermore, as T regulatory cells (Tregs) are required for tolerance and dampening of 
effector T cell responses [50], we used flow cytometry to identify whether PS could augment 
the quantity of Tregs in our MOG assay. Twenty five micromolar PS-loaded 80 × 320 nm 
PLGA nanorods significantly increased the IL-10 and FOXP3 double-positive cell 
population that corresponds to T regulatory cells, whereas an equivalent dose of liposomal 
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PS did not cause an increase in the Treg population (Fig. 3B). It should be noted that the 
abrogation of IL-2 by PS nanorods will greatly reduce the proliferation of all T cell 
populations. Thus the overall number of Tregs may be unchanged but the relative number is 
heightened by PS nanorods due to the lack of effector T cell proliferation in comparison to 
the other treatment arms. As the balance between an effector response versus a tolerizing T 
regulatory response is dependent in part on the quantity of T cells, the relative abundance of 
effector versus Tregs and the cytokine milieu, it is plausible that particulate delivery of PS 
may help shift the balance towards tolerance through both reducing effector T cell 
proliferation and the amount of effector skewing cytokines [50,51]. These data clearly show 
that delivery of PS on a nanorod potently diminishes inflammatory cytokines and promotes 
Treg population abundance during an established effector T cell response that does not occur 
when an equivalent dose of PS is delivered on a liposome.
To further clarify whether this immune dampening effect was dependent on particle 
geometry, we fabricated 1 micron PLGA cylinders with PS and performed the same 
experiment (Fig. 3C). Interestingly, these 1 micron cylinders had an intermediate efficacy 
compared to liposomal PS and the 80 × 320 nm nanorods. For example, IL-2, IL-6 and 
TNFα release were diminished by 1 micron cylinder delivery of 12.5 μM PS, but to a 
significantly less level than for an equivalent dose of PS delivered by 80 × 320 nm nanorods. 
Conversely, liposomal PS was the least efficacious platform for all cytokines tested. At least 
four conclusions may be drawn from these findings: 1) There is a signaling threshold for the 
immune-suppressive effects of PS; 2) this threshold is achieved at much lower doses when 
PS is delivered via a PLGA nanorod particle; 3) the geometry of the particle itself may alter 
this threshold; and 4) the signaling pathways leading to production of individual cytokines 
may be differentially affected by particle geometry and ligand dose.
3.4. Suppression of autoimmune responses in vivo
Building on our previous findings, we next hypothesized that the 80 × 320 nm PS-loaded 
PLGA nanorods may be able to dampen autoimmune pathology. Multiple sclerosis is the 
most common autoimmune inflammatory demyelinating disease of the CNS. The 
pathogenesis of MS is driven by auto-reactive T cells and auto-antibodies creating multifocal 
areas of demyelination with loss of oligodendrocytes, astroglial scarring, and axonal injury 
[52,53]. It was recently discovered that myelin phospholipids are targeted by the 
autoimmune response in MS and that myelin phospholipids are natural anti-inflammatory 
class of compounds with the ability to suppress activation and inducing apoptosis of 
autoreactive T cells in MS [54–56]. Pertinently, PS was identified as one of the targeted 
myelin lipids and was among the most highly active in suppressing activation and inducing 
apoptosis of autoreactive T cells [56]. However, the ability to harness PS as a therapeutic 
component for MS has yet to be fully explored, possibly in part because of the ability of 
soluble PS to trigger clot formation [57].
To test whether particulate delivery of PS could ameliorate CNS disease, we used the 
experimental autoimmune encephalitis (EAE) model in C57BL/6 as it is the most common 
and well-characterized animal model of multiple sclerosis (MS) and has been used in the 
development of MS therapies [58]. Similar to MS patients, these mice suffer immune-cell 
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mediated lesions to white matter tracts of central nervous system tissue (CNS). The CNS 
tissue damage causes ascending limb paralysis which is evaluated by a standard clinical 
scoring system as described in the Methods section. Mice were intravenously treated with 50 
μg of liposomal PS (PS LIPO), blank PLGA particles (BLK PRINT), or 50 μg of 80 × 320 
nm PS-loaded PLGA nanorods (PS Nanorod) at times post-immunization as indicated by 
arrows in Fig. 4A. In addition, the disease incidence, day on onset, and maximum score of 
mice are shown in Fig. 4A and B. Mice treated with PS PRINT particles had a significantly 
lower burden of disease based on clinical scores and video evidence of reduced hind limb 
paralysis (Supplemental movie 1). Furthermore, the reduction in clinical severity was 
significantly more pronounced and occurred earlier after treatment in the group that received 
nanorod PS versus an equivalent dose of liposomal PS. These findings provide in vivo 
evidence for the use of particulate PS to ameliorate pathologic autoimmune responses with 
concomitant improvement in CNS function.
Supplementary data related to this article can be found online at http://dx.doi.org/10.1016/
j.biomaterials.2015.08.040.
3.5. Suppression of allogenic human CD4+ T cell activation via particulate delivery of PS
Given the above findings showing the capability for 80 × 320 nm nanorod delivery of PS to 
impede inflammatory innate immune responses and subsequent effector T cell proliferation, 
we hypothesized that this approach may be useful in abrogating the immune pathology 
caused by aberrant T cell activation in some human diseases. A proof of concept study using 
a mixed lymphocyte reaction to assess allogeneic human CD4+ T cell activation was 
performed using healthy human blood donors. In this experiment, mixing T cells from one 
donor with DCs from another donor will trigger activation and proliferation of T cells as 
they recognize the DC as foreign due to MHC incompatibility [59].
While blank PLGA nanorods and liposomal PS similarly and modestly decreased 
proliferation of T cells from ~61% in the untreated group to ~50%, PS-loaded PLGA 
nanorods (PS Nanorod) significantly reduced T-cell activation and proliferation all the way 
to baseline levels of ~3% (Fig. 5A). This lack of T cell proliferation and activation was 
further evidenced by the significant reduction in IFNγ production seen only in the PS 
Nanorod group (Fig. 5B). These robust findings provide further evidence for the clear 
difference in biological signaling triggered by geometric manipulation of an equivalent dose 
of PS on a PLGA nanorod versus a liposome. That this work was carried out in primary 
human cells suggests that this may be a potential approach for reducing human T cell 
activation such as in transplant rejection and graft versus host disease.
4. Discussion
Given the exciting potential for nanomaterial-based biological programming, it is critical to 
elucidate how particulate presentation of ligands may affect subsequent signaling from 
cognate receptors. Our aim in this report was to determine whether particulate presentation 
of a model cell surface receptor ligand, phosphatidylserine, would augment downstream 
signaling effects and whether this could be used for therapeutic benefit. We made use of the 
PRINT fabrication process which exquisitely controls particle, size, shape and composition. 
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This enabled us to directly compare biological responses to equivalent doses of PS delivered 
in liposomal or PLGA particle fashion. By adjusting particle size and shape, we could 
further tease out whether the geometry of PS presentation itself can tune signaling events. 
While previous studies have looked at liposomal formulations of PS, none to our knowledge 
have directly compared the signaling efficacy of liposomal PS versus PS-loaded PLGA 
particles on immune responses nor controlled as we have for particle geometry [33–35]. 
Through our studies, we identified a clear and significant enhancement of the anti-
inflammatory and T cell dampening effects of PS by manipulation of its geometric 
presentation to innate immune cells that may be of therapeutic benefit in a variety of disease 
contexts.
Our studies consistently found that for an equivalent dose of PS, its presentation on an 80 × 
320 nm PLGA nanorod was significantly more efficacious than a liposomal or 1 micron 
PLGA cylinder formulation. This may indicate geometric manipulation of PS confers 
emergent properties upon the ligand through augmenting its interactions with its cell surface 
receptors. Such a finding would be in line with a large body of evidence addressing cellular 
signaling pathways downstream of cell surface receptors. For example, the fungal cell wall 
moiety beta-glucan requires particulate presentation in order to trigger signaling through its 
cognate pattern recognition receptor Dectin-1 [60]. The particulate presentation of beta-
glucan enables formation of a phagocytic synapse through receptor clustering of Dectin-1 
only in the presence of intact fungi. Elegantly, this mechanism enables innate immune cells 
to trigger anti-fungal responses only when they encounter an intact fungus as opposed to 
simply a soluble component of the fungal cell wall.
As inflammation drives both innate immune and effector T cell responses but also tissue 
pathology, finding means of countering inflammatory programs in situ would be of great 
benefit [48]. While standard clinical options for excessive inflammation or undesired 
immune responses include systemic immunosuppression or systemic blockade of cytokines, 
more targeted and transient solutions are sorely needed. Our studies addressing the potential 
for PS particles to dampen effector immune responses using the 2D2 transgenic T cells, an 
in vivo model of multiple sclerosis, and an assay of organ rejection provide strong evidence 
that geometric manipulation of PS may be an attractive modality for quenching pathologic 
inflammatory responses and undesired effector T cell proliferation to promote Treg 
abundance.
Our studies suggest PS particles themselves drive an anti-inflammatory program that is 
antigen-independent, which may explain why the clinical improvement in the EAE model 
was limited to a short window after dosing with PS stopped. Two recent papers from the 
Miller group showed a transient efficacy in the EAE model when using a nanoparticle 
platform that depleted inflammatory cells whereas an antigen-dependent nanoparticle 
approach did not require continued dosing for efficacy [19,23]. Further studies are underway 
to address whether PS particles co-delivering an antigen could drive antigen-specific 
immune tolerance. Regardless, the potential therapeutic use of biomaterials to program 
tolerance in the setting of autoimmunity and transplantation could fundamentally improve 
the clinical outcomes for millions of patients [25,61].
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We show that particulate presentation of PS on 80 × 320 nm PLGA nanorods enhances its 
signaling efficacy to dampen inflammation and promote immune tolerance through 
inhibiting effector T cell expansion while maintaining T regulatory cells. These effects are 
dependent on the geometry of PS presentation as PS liposomes and PS delivered on a 1 
micron PLGA cylinder are less efficacious for a given PS dose than 80 × 320 nm nanorods. 
Geometric manipulation of PS was used therapeutically to reduce disease in a model of 
multiple sclerosis and also to block effector T cell responses in primary human immune cells 
in an allogenic mixed lymphocyte reaction. These results not only identify a promising 
therapeutic strategy for a variety of immune-related conditions but also give evidence for 
manipulation of ligand geometry via biomaterials as a means to tailor programming of 
cellular signaling networks. The ability to tune the kinetics and magnitude of cellular 
signaling may afford unforeseen advantages in future therapeutics given these features are 
critical to encoding cellular function [62].
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SEM images of PRINT particles. A. Blank and PS-loaded 80 × 320 nm nanorods. B. Blank 
and PS-loaded 1 micron cylinders.
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PS nanorods downregulate inflammatory responses in dendritic cells. A. ELISA analysis of 
IL-6 (left) and IL-12(p40) (right) in DC cultures stimulated with LPS(10 ng/ml) and 
IFNγ(10 ng/ml) for 18 h. PS was dosed at 25 μM in either liposomal (PS LIPO) or 80 × 20 
nm nanorod formulation (PS Nanorod). Blank 80 × 320 nm PLGA particles (BLK PRINT) 
were used as a negative control. B. Flow cytometry-based histogram analysis of surface 
expression of CD86. Cells were initially gated as CD11c+. MFI represents Mean Fluorescent 
Intensity. Results are representative of three independent experiments. Error bars represent ± 
s.e.m. * = P < .0001.
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Geometric manipulation of PS downregulates myelin-specific T cell activation and cytokine 
responses. A. ELISA analysis of 2D2 Tg CD4+ T cells activated with MOG35–55-pulsed 
DCs. Supernatants were collected 48 hpi. PS doses ranged from 12.5 to 50 μM in either 
liposomal (PS LIPO) or 80 × 20 nm nanorod formulation (PS Nanorod). B. Left, contour 
plot depicting intracellular flow cytometry-based of IL-10+, FoxP3+ population. Right, 
quantification of IL-10+, FoxP3+ cell population. Cells were initially gated as CD3+. C. 
ELISA analysis of 2D2 Tg CD4+ T cells activated with MOG35–55-pulsed DCs. 
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Supernatants were collected 48 hpi. PS doses ranged from 12.5 to 50 μM in liposomal, 80 × 
320 nm PLGA nanorod or 1 μm PLGA cylinder formulations. Results are representative of 
three independent experiments. Error bars represent ± s.e.m. * = P < .05; ** = P < .01; *** = 
P < .001; *** = P <.0001.
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PS Nanorods suppress autoimmune responses in vivo. A. Clinical scores of mice treated as 
indicated. Scores represent the combination of two independent experiments of 5–6 mice per 
group. Mice were intravenously treated with 50 μg of liposomal PS (PS LIPO), 50 μg of PS 
on 80 × 320 nm PLGA nanorods (PS Nanorod), or an equivalent dose of Blank PLGA 
particles (BLK PRINT) at times indicated by arrows. B. Table depicting disease incidence, 
day on onset, and maximum score of mice depicted in panel A.
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PS Nanorods are efficacious in reducing the activation of human immune cells. A. CFSE 
dilution analysis of allogenic human CD4+ T cell activation 7 days post activation. B. 
ELISA analysis of allogenic CD4+ T cell activation. Supernatants were collected 7 days post 
activation. Results are representative of two independent experiments with four CD4+ T cell 
donors and two DC donors. Cells were initially gated as CD3+. Error bars represent ± s.e.m. 
* = P < .05.
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Table 1
PRINT particle characteristics.
Formulation Size (nm) PDI Zeta potential (mV) Weight % PS
80 × 320 nm Blank PLGA nanorod 208.3 ± 3.0 0.104 –6.3 ± 1.001 0
80 × 320 nm PS PLGA nanorod 209.1 ± 3.1 0.048 –22.0 ± 2.423 8.0 ± 2.1
1 μm Blank PLGA cylinder 1202 ± 31.1 0.684 –31.8 ± 0.173 0
1 μm PS PLGA cylinder 1272 ± 35.8 0.714 –39.4 ± 0.651 11.2 ± 3.0.2
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